Spinal Muscular Atrophy Foundation

Quick Stats

• Annual Giving: $2.8 million (2024)
• Total Research Investment: $150 million since 2003
• Decision Time: Not publicly disclosed (invitation-only process)
• Grant Range: $300,000 - $15 million
• Geographic Focus: International (primarily US)

Contact Details

• Website: smafoundation.org
• Phone: 646-253-7100 or toll-free: 877-FUND-SMA (877-386-3762)
• Email: info@smafoundation.org
• Address: 888 Seventh Avenue, Suite 400, New York, NY 10019
• Research Inquiries: Submit letter of intent to info@smafoundation.org

Overview

The Spinal Muscular Atrophy Foundation is the world's leading private funder of SMA research, having invested approximately $150 million since its founding in 2003. Operating as a unique hybrid between a nonprofit organization and venture capital firm, the Foundation has played a pivotal role in developing three FDA-approved SMA treatments. Founded by parents of children with SMA, it employs a strategic, results-oriented approach to funding late-stage translational research with immediate clinical impact. With total assets of $50 million and annual charitable disbursements of $2.8 million, the Foundation focuses exclusively on accelerating therapeutic development for SMA, transforming what was once the leading genetic killer of infants into a treatable condition.

Funding Priorities

Grant Programs

• Strategic Research Partnerships: $8.5 million - $15 million (multi-year collaborations with pharmaceutical companies and major academic centers)
• Stanford Innovative Medicines Accelerator Projects: Up to $300,000 (one-year awards for drug discovery)
• Research Infrastructure Development: Variable amounts for creating essential research tools, mouse models, and biomarkers
• Application method: Invitation-only, principal investigators submit letters of intent

Priority Areas

• Late-stage translational research with immediate clinical impact
• Drug discovery and therapeutic development
• Clinical trial support and development
• Regenerative medicine approaches for SMA
• Development of research tools and infrastructure (mouse models, biomarkers, assays)
• Strategic partnerships with pharmaceutical companies for drug development

What They Don't Fund

• Basic science research without clear therapeutic pathway
• Research unrelated to SMA or closely related neuromuscular disorders
• General operating support for organizations
• Patient services or direct patient assistance
• Educational programs unrelated to drug development
• Advocacy work

Governance and Leadership

Founders:

• Loren A. Eng (President) - Co-founder, mother of child with SMA
• Dinakar Singh (Chairman) - Co-founder, father of child with SMA, Founding Partner TPG-Axon Capital

Executive Leadership:

• Karen S. Chen, PhD - CEO, 35+ years research experience, former Director of Neurosciences at Roche
• Omar Khwaja, MD PhD - Chief Medical Officer, pediatric neurologist, former Global Head of Rare Diseases at Roche
• Kelly Howell, PhD - Director, 15 years neurodevelopment research experience

Board includes: Douglas G. Cole, MD (Flagship Ventures), Gerald Fischbach, MD (Simons Foundation), Story Landis, PhD (former NINDS Director), Jonathan S. Leff (Deerfield Management)

Application Process & Timeline

How to Apply

This funder does not have a public application process. Grants are awarded through an invitation-only system. Only principal investigators are eligible to apply by submitting a letter of intent to info@smafoundation.org. The Foundation strategically identifies and partners with researchers and institutions whose work aligns with their therapeutic development goals.

Getting on Their Radar

• Submit letter of intent outlining research proposal focused on late-stage translational work to info@smafoundation.org
• The Foundation actively partners with nearly every pharmaceutical company working on SMA globally
• They collaborate with leading academic medical centers including Columbia, Stanford, Harvard, and Boston Children's Hospital
• Priority given to researchers with strong track records in drug discovery and development
• Foundation operates like a venture capital firm, seeking strategic partnerships rather than responding to unsolicited proposals

Decision Timeline

Not publicly disclosed - varies based on strategic priorities and partnership negotiations

Success Rates

Not publicly disclosed due to invitation-only application process

Reapplication Policy

Not publicly disclosed; relationships appear to be ongoing with successful partners

Application Success Factors

Based on the Foundation's track record and funded projects:

• Late-stage focus is critical: The Foundation explicitly states they fund "work with immediate impact on late translational or clinical research"
• Drug discovery expertise required: Successful partners include PTC Therapeutics ($11.7 million total), Genentech (Evrysdi development), and Biogen/Ionis (Spinraza)
• Strategic alignment essential: Projects must fit into the Foundation's overall therapeutic development strategy
• Principal investigator credentials matter: Led by researchers with proven track records in translational research
• Measurable outcomes expected: The Foundation operates with a venture capital mindset, expecting tangible progress toward therapeutics
• Regenerative medicine is current frontier: With three approved therapies available, focus has shifted to next-generation treatments
• Infrastructure development valued: Foundation has invested $30+ million in research tools that benefit the entire field

Key Takeaways for Grant Writers

• This is an invitation-only funder requiring strategic relationship building before any application
• Focus must be on late-stage translational research with clear path to clinical trials
• The Foundation operates more like a biotech company than traditional grant maker
• Success requires principal investigators with strong drug development credentials
• Projects should complement existing SMA therapies rather than duplicate them
• Multi-million dollar partnerships possible for aligned strategic initiatives
• Consider collaborating with their existing partners (Columbia, Stanford, Harvard) to gain entry

References

• SMA Foundation Official Website (smafoundation.org) - Accessed February 2024
• ProPublica Nonprofit Explorer - Form 990-PF filings for 2024
• Columbia University Medical Center Press Release - "$15 million SMA grant" (2006)
• PTC Therapeutics Partnership Announcement - "$8.5 million collaboration"
• Harvard Business School Case Study - "SMA Foundation: Venture Philanthropy"
• Nature Index - SMA Foundation Research Profile
• Grantmakers.io - Foundation Profile and Grant History
• Stanford Innovative Medicines Accelerator Partnership Details